Three-Monthly Long-Acting Formulation of Paliperidone Palmitate is a Dominant Treatment Option, Cost Saving while Adding Qalys, Compared to the One-Monthly Formulation in the Treatment of Schizophrenia in Belgium- A Cost-Utility Study
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1041
https://www.valueinhealthjournal.com/article/S1098-3015(16)32407-X/fulltext
Title :
Three-Monthly Long-Acting Formulation of Paliperidone Palmitate is a Dominant Treatment Option, Cost Saving while Adding Qalys, Compared to the One-Monthly Formulation in the Treatment of Schizophrenia in Belgium- A Cost-Utility Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32407-X&doi=10.1016/j.jval.2016.09.1041
First page :
A526
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
977